论文部分内容阅读
目的系统评价贝伐珠单抗联合顺铂腔内注射治疗非小细胞肺癌胸腔积液的有效性和安全性。方法计算机检索PubMed、Embase、Cochrane图书馆、万方数据库、中国学术文献出版总库(China National Knowledge Infrastructure,CNKI)、中国生物医学文献数据库(Chinese Biomedical Literature Database)、维普电子期刊全文数据库等。2名评价员独立评价纳入研究的文献质量并提取资料,使用RevMan5.3软件进行统计分析。结果共纳入6项随机对照试验(randomized control trial,RCT),共371例患者。Meta分析结果显示:贝伐珠单抗联合顺铂能显著提高非小细胞肺癌胸腔积液治疗的有效率(OR=3.40,95%CI:2.12~5.45,P<0.00001),明显降低胸腔积液内血管内皮生长因子(vascular endothelial growth factor,VEGF)的含量(MD=59.53,95%CI:42.85~76.22,P<0.00001),同时不会增加不良反应的发生率。结论贝伐珠单抗联合顺铂腔内注射可以缓解和控制恶性胸水,且安全性良好。
Objective To evaluate the efficacy and safety of bevacizumab plus cisplatin in the treatment of pleural effusion in non-small cell lung cancer. Methods We searched PubMed, Embase, Cochrane Library, Wanfang Database, CNKI, Chinese Biomedical Literature Database and VIP Electronic Journal Full-text Database. Two reviewers independently assessed the quality of the included literature and extracted the data for statistical analysis using RevMan 5.3 software. Results A total of 6 randomized controlled trials (RCTs) were enrolled in this study. A total of 371 patients were included. Meta-analysis showed that the combination of bevacizumab and cisplatin could significantly improve the efficiency of pleural effusion in non-small cell lung cancer (OR = 3.40, 95% CI: 2.12-5.45, P <0.00001) and significantly reduce pleural effusion (VEGF = 59.53, 95% CI: 42.85 ~ 76.22, P <0.00001) without increasing the incidence of adverse reactions. Conclusion Bevacizumab combined with cisplatin intracavitary injection can relieve and control malignant pleural effusion, and the safety is good.